Shanghai Pharmaceuticals Holding Co., Ltd

Equities

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
17.79 CNY +1.77% Intraday chart for Shanghai Pharmaceuticals Holding Co., Ltd +6.40% +6.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Pharma's Profit Plunges 33% in 2023 Despite 12% Revenue Growth; Shanghai Shares Rise 4% MT
Shanghai Pharmaceuticals Holding Co., Ltd Proposes Final Dividend for the Year Ended 31 December 2023, Payable Before 30 August 2024 CI
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Pharmaceuticals Gets Nod to Register Amiodarone Hydrochloride Injection MT
Shanghai Pharma Names Chairman; Vice Chairman Resigns MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Executive Changes CI
Shanghai Pharma Unit's Citicoline Sodium Injection Passes Regulatory Evaluation MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Principal Place of Business in Hong Kong CI
Shanghai Pharma Receives Approval For New Dosage of Leukemia Drug MT
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Joint Company Secretary CI
Shanghai Pharmaceuticals Holding Gets Fine for Anti-Monopoly Violations MT
China Aproves Phase 1 Clinical Trial of Shanghai Pharma Subsidiary's Capsule for Tumors MT
Shanghai Pharma's Ex-Vice President Becomes Sixth Senior Exec to Face Probe MT
Shanghai Pharmaceuticals Chairman Steps Down MT
SIIC Environment Chairman Resigns MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Zhou Jun as the Chairman of the Company, A Non-Executive Director CI
Shanghai Pharmaceuticals' Profit Up 6% in Q3 MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shanghai Pharma’s Arthrits Drug Passes Generic Drug Consistency Test MT
Shanghai Pharma’s Antibiotic Passes Generic Drug Consistency Evaluation in China MT
China's CMOC to boost Congo copper output after ending row with Gecamines RE
Shanghai Pharma’s Former Execs Face Probe MT
Shanghai Pharmaceuticals’ H1 Profit Slides 29% Despite 19% Revenue Growth; Shanghai Shares Slump 8% MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chart Shanghai Pharmaceuticals Holding Co., Ltd
More charts
Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.79 CNY
Average target price
20.78 CNY
Spread / Average Target
+16.81%
Consensus
  1. Stock Market
  2. Equities
  3. 601607 Stock
  4. News Shanghai Pharmaceuticals Holding Co., Ltd
  5. S.I. Yangtze River Completes Acquisition of 40% in Shanghai Pharmaceuticals’ Controlling Shareholder